Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
7.90B | 7.62B | 7.50B | 7.96B | 6.39B | 5.79B | Gross Profit |
4.88B | 3.65B | 3.47B | 3.34B | 2.99B | 2.86B | EBIT |
1.57B | 1.52B | 1.56B | 1.51B | 1.33B | 1.30B | EBITDA |
3.58B | 3.54B | 3.40B | 3.18B | 2.81B | 2.53B | Net Income Common Stockholders |
1.21B | 1.18B | 1.15B | 1.07B | 990.00M | 871.00M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
23.00M | 7.00M | 25.00M | 250.00M | 8.00M | 139.00M | Total Assets |
45.66B | 44.60B | 40.83B | 37.90B | 35.73B | 32.03B | Total Debt |
17.00M | 18.72B | 16.51B | 15.10B | 13.61B | 11.58B | Net Debt |
-6.00M | 18.71B | 16.48B | 15.09B | 13.60B | 11.44B | Total Liabilities |
33.32B | 32.35B | 29.35B | 27.27B | 25.91B | 22.95B | Stockholders Equity |
12.22B | 12.11B | 11.35B | 10.51B | 9.70B | 8.94B |
Cash Flow | Free Cash Flow | ||||
-1.81B | -1.56B | -1.21B | -1.12B | -1.86B | -1.57B | Operating Cash Flow |
1.82B | 2.76B | 2.56B | 2.26B | 1.66B | 1.73B | Investing Cash Flow |
-4.64B | -4.46B | -3.80B | -3.37B | -3.53B | -3.33B | Financing Cash Flow |
1.96B | 1.75B | 1.29B | 1.17B | 1.72B | 1.73B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
74 Outperform | $25.63B | 25.89 | 7.00% | 3.01% | 5.62% | 30.02% | |
72 Outperform | $26.64B | 21.36 | 10.23% | 2.82% | 8.96% | 3.75% | |
72 Outperform | $28.29B | 18.41 | 13.28% | 3.10% | 11.16% | 20.94% | |
71 Outperform | $23.31B | 27.40 | 5.63% | 4.57% | 10.82% | ― | |
70 Neutral | $24.30B | 22.40 | 8.69% | 4.04% | 7.92% | 1.54% | |
67 Neutral | $24.52B | 25.26 | 9.22% | 2.21% | 4.76% | 4.08% | |
64 Neutral | $8.54B | 10.24 | 4.67% | 4.36% | 4.12% | -13.19% |
On May 12, 2025, Ameren entered into forward sale agreements with major financial institutions including Goldman Sachs, JPMorgan Chase, Barclays, and Wells Fargo, involving the sale of Base Shares and Option Shares. These agreements, part of a broader strategy to manage stock issuance and pricing, allow Ameren to settle by issuing shares or through cash or net share settlements by January 15, 2027. The initial forward sale price is set at $91.885 per share, subject to adjustments based on interest rates and expected dividends. The agreements also include provisions for acceleration and settlement adjustments based on market conditions and corporate actions. The transactions, which were part of a registered public offering, were executed under a Registration Statement effective since October 13, 2023.
The most recent analyst rating on (AEE) stock is a Buy with a $91.00 price target. To see the full list of analyst forecasts on Ameren stock, see the AEE Stock Forecast page.
On April 22, 2025, Noelle K. Eder informed Ameren Corporation’s Board of Directors of her resignation as a director, effective May 6, 2025. Her departure is due to personal reasons related to a change in her primary employment requiring her to live outside the United States, and not due to any disagreements with the company.